MCK
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. 1 purchase disclosure year to date, a thin reading
- Financial indicators Pulls against a bullish reading. Current ratio 0.85 · operating margin 1.6%
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
VENTE TOTALE: 8 764 titres (~6 984 488,10 $ US)
- Insiders
- Lerman Bradley ETYLER BRIAN S.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$6,984,488
Avg sell (VWAP, 90d window) $798.13 vs last close —
- Last activity
- 2026-08-10
- Last synced
-
2026-08-16 09:56:14
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-08 | Rutledge Napoleon B JR | Sell | 111 | $891.45 | $98,951 | Form 4 |
| 2026-08-10 | Lerman Bradley E | Sell | 301 | $892.33 | $268,590 | Form 4 |
| 2026-07-07 | TYLER BRIAN S. | Sell | 8,463 | $793.56 | $6,715,898 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-09-13
MCK presents a moderately constructive setup: a solid earnings beat with raised FY27 guidance on specialty/pharma growth provides a credible near-term catalyst (score 70, confidence 0.75), while stable cash flow…
The first sentence of the analysis written for MCK on 2026-09-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 3.6% | 3.5% | 3.9% | 4.3% | 4.8% | |
| Ebit Margin | 1.6% | 1.3% | 1.3% | 1.8% | 0.8% | |
| Ebitda Margin | 1.8% | 1.5% | 1.5% | 2.1% | 1.2% | |
| Operating Profit Margin | 1.6% | 1.2% | 1.3% | 1.6% | 1.0% | |
| Pretax Profit Margin | 1.5% | 1.2% | 1.2% | 1.7% | 0.7% | |
| Continuous Operations Profit Margin | 1.3% | 1.0% | 1.0% | 1.3% | 0.5% | |
| Net Profit Margin | 1.2% | 0.9% | 1.0% | 1.3% | 0.4% | |
| Bottom Line Profit Margin | 1.2% | 0.9% | 1.0% | 1.3% | 0.4% | |
| Current Ratio | 0.854 | 0.899 | 0.916 | 0.924 | 0.954 | |
| Quick Ratio | 0.492 | 0.526 | 0.512 | 0.513 | 0.568 | |
| Solvency Ratio | 0.066 | 0.051 | 0.053 | 0.069 | 0.032 | |
| Cash Ratio | 0.059 | 0.092 | 0.088 | 0.098 | 0.073 | |
| Price To Earnings Ratio | 22.448 | 26.024 | 23.802 | 14.112 | 41.878 | |
| Price To Earnings Growth Ratio | 0.457 | 1.767 | -2.232 | 0.058 | -0.330 | |
| Forward Price To Earnings Growth Ratio | 0.457 | 1.767 | -2.232 | 0.058 | -0.330 | |
| Price To Earnings Diluted Ratio | 22.547 | 26.166 | 23.961 | 14.219 | 42.342 | |
| Price To Earnings Diluted Growth Ratio | 0.458 | 1.759 | -2.264 | 0.058 | -0.334 | |
| Price To Book Ratio | -49.244 | -41.340 | -36.256 | -27.054 | -20.521 | |
| Price To Sales Ratio | 0.265 | 0.239 | 0.231 | 0.182 | 0.177 | |
| Price To Free Cash Flow Ratio | 18.702 | 16.406 | 19.702 | 10.919 | 11.958 | |
| Price To Operating Cash Flow Ratio | 17.377 | 14.090 | 16.565 | 9.738 | 10.515 | |
| Debt To Assets Ratio | 0.105 | 0.098 | 0.110 | 0.117 | 0.119 | |
| Debt To Equity Ratio | -3.966 | -3.563 | -3.749 | -3.928 | -3.320 | |
| Debt To Capital Ratio | 1.337 | 1.390 | 1.364 | 1.341 | 1.431 | |
| Long Term Debt To Capital Ratio | 1.740 | 1.868 | 1.546 | 1.671 | 1.809 | |
| Financial Leverage Ratio | -37.902 | -36.230 | -34.218 | -33.560 | -27.860 | |
| Working Capital Turnover Ratio | -50.388 | -67.790 | -76.739 | -93.800 | -552.230 | |
| Operating Cash Flow Ratio | 0.092 | 0.099 | 0.082 | 0.108 | 0.091 | |
| Operating Cash Flow Sales Ratio | 0.015 | 0.017 | 0.014 | 0.019 | 0.017 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.929 | 0.859 | 0.841 | 0.892 | 0.879 | |
| Debt Service Coverage Ratio | 4.013 | 3.022 | 13.782 | 3.972 | 2.529 | |
| Interest Coverage Ratio | 26.130 | 17.078 | 16.160 | 17.956 | 15.298 | |
| Short Term Operating Cash Flow Coverage Ratio | 4.858 | 5.109 | 86.280 | 5.330 | 5.549 | |
| Operating Cash Flow Coverage Ratio | 0.715 | 0.823 | 0.584 | 0.707 | 0.588 | |
| Capital Expenditure Coverage Ratio | 14.117 | 7.084 | 6.279 | 9.246 | 8.288 | |
| Dividend Paid And Capex Coverage Ratio | 7.534 | 5.054 | 4.310 | 6.069 | 5.461 | |
| Dividend Payout Ratio | 0.080 | 0.105 | 0.105 | 0.082 | 0.249 | |
| Enterprise Value Multiple | 15.549 | 16.652 | 15.913 | 9.216 | 16.297 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 3.6% | ▲0.1% | ▼-0.4% |
| Ebit Margin | 1.6% | ▲0.3% | ▲0.2% |
| Ebitda Margin | 1.8% | ▲0.3% | ▲0.2% |
| Operating Profit Margin | 1.6% | ▲0.4% | ▲0.2% |
| Pretax Profit Margin | 1.5% | ▲0.3% | ▲0.3% |
| Continuous Operations Profit Margin | 1.3% | ▲0.3% | ▲0.2% |
| Net Profit Margin | 1.2% | ▲0.3% | ▲0.2% |
| Bottom Line Profit Margin | 1.2% | ▲0.3% | ▲0.2% |
| Current Ratio | 0.854 | ▼-0.046 | ▼-0.056 |
| Quick Ratio | 0.492 | ▼-0.033 | ▼-0.030 |
| Solvency Ratio | 0.066 | ▲0.015 | ▲0.012 |
| Cash Ratio | 0.059 | ▼-0.033 | ▼-0.023 |
| Price To Earnings Ratio | 22.448 | ▼-3.577 | ▼-3.205 |
| Price To Earnings Growth Ratio | 0.457 | ▼-1.309 | ▲0.513 |
| Forward Price To Earnings Growth Ratio | 0.457 | ▼-1.309 | ▲0.513 |
| Price To Earnings Diluted Ratio | 22.547 | ▼-3.619 | ▼-3.300 |
| Price To Earnings Diluted Growth Ratio | 0.458 | ▼-1.301 | ▲0.523 |
| Price To Book Ratio | -49.244 | ▼-7.904 | ▼-14.361 |
| Price To Sales Ratio | 0.265 | ▲0.026 | ▲0.046 |
| Price To Free Cash Flow Ratio | 18.702 | ▲2.296 | ▲3.165 |
| Price To Operating Cash Flow Ratio | 17.378 | ▲3.287 | ▲3.720 |
| Debt To Assets Ratio | 0.105 | ▲0.006 | ▼-0.005 |
| Debt To Equity Ratio | -3.966 | ▼-0.403 | ▼-0.261 |
| Debt To Capital Ratio | 1.337 | ▼-0.053 | ▼-0.036 |
| Long Term Debt To Capital Ratio | 1.740 | ▼-0.128 | ▲0.013 |
| Financial Leverage Ratio | -37.902 | ▼-1.672 | ▼-3.948 |
| Working Capital Turnover Ratio | -50.388 | ▲17.402 | ▲117.802 |
| Operating Cash Flow Ratio | 0.092 | ▼-0.007 | ▼-0.003 |
| Operating Cash Flow Sales Ratio | 0.015 | ▼-0.002 | ▼-0.001 |
| Free Cash Flow Operating Cash Flow Ratio | 0.929 | ▲0.070 | ▲0.049 |
| Debt Service Coverage Ratio | 4.013 | ▲0.990 | ▼-1.451 |
| Interest Coverage Ratio | 26.130 | ▲9.051 | ▲7.605 |
| Short Term Operating Cash Flow Coverage Ratio | 4.858 | ▼-0.251 | ▼-16.567 |
| Operating Cash Flow Coverage Ratio | 0.715 | ▼-0.109 | ▲0.031 |
| Capital Expenditure Coverage Ratio | 14.117 | ▲7.033 | ▲5.114 |
| Dividend Paid And Capex Coverage Ratio | 7.534 | ▲2.480 | ▲1.848 |
| Dividend Payout Ratio | 0.080 | ▼-0.025 | ▼-0.044 |
| Enterprise Value Multiple | 15.549 | ▼-1.102 | ▲0.824 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $106.96B | $85.74B | $71.46B | $50.24B | $46.62B | |
| Enterprise value | $111.60B | $87.44B | $74.27B | $52.86B | $50.63B | |
| EV / Sales | 0.28x | 0.24x | 0.24x | 0.19x | 0.19x | |
| EV / Op. cash flow | 18.13x | 14.37x | 17.21x | 10.24x | 11.42x | |
| EV / Free cash flow | 19.51x | 16.73x | 20.48x | 11.49x | 12.99x | |
| EV / EBITDA | 15.55x | 16.65x | 15.91x | 9.22x | 16.30x | |
| Net debt / EBITDA | 0.65x | 0.32x | 0.60x | 0.46x | 1.29x | |
| Current ratio | 0.85x | 0.90x | 0.92x | 0.92x | 0.95x | |
| Income quality | 1.29x | 1.75x | 1.36x | 1.39x | 3.44x | |
| Graham net-net | -$373 | -$317 | -$283 | -$246 | -$251 | |
| Tax burden | 76.8% | 75.6% | 79.2% | 76.9% | 57.8% | |
| Interest burden | 96.2% | 94.5% | 94.0% | 94.9% | 91.5% | |
| Working capital | -$9.81B | -$6.21B | -$4.39B | -$3.67B | -$2.23B | |
| Invested capital | $10.31B | $9.56B | $11.90B | $12.37B | $12.91B | |
| Return on assets | 5.8% | 4.4% | 4.5% | 5.7% | 1.8% | |
| Operating ROA | 8.2% | 6.1% | 6.1% | 7.1% | 4.2% | |
| Return on tangible assets | 7.1% | 5.2% | 5.4% | 7.1% | 2.2% | |
| Return on equity | -219.2% | -158.9% | -152.3% | -191.7% | -49.0% | |
| Return on invested capital | 31.5% | 23.3% | 21.2% | 22.9% | 11.5% | |
| Return on capital employed | 42.2% | 32.3% | 26.0% | 31.0% | 18.4% | |
| Earnings yield | 4.5% | 3.8% | 4.2% | 7.1% | 2.4% | |
| Free cash flow yield | 5.3% | 6.1% | 5.1% | 9.2% | 8.4% | |
| Capex / Op. cash flow | 7.1% | 14.1% | 15.9% | 10.8% | 12.1% | |
| Capex / Depreciation | 59.8% | 135.1% | 108.2% | 91.8% | 70.4% | |
| Capex / Sales | 0.1% | 0.2% | 0.2% | 0.2% | 0.2% | |
| SG&A / Sales | -2.0% | 2.2% | 2.7% | 2.6% | 3.7% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% | |
| Intangibles / Total assets | 18.7% | 15.3% | 18.2% | 19.6% | 18.2% | |
| Days sales outstanding | 25d | 26d | 26d | 26d | 26d | |
| Days payables outstanding | 56d | 58d | 58d | 59d | 55d | |
| Operating cycle | 48d | 50d | 52d | 53d | 53d | |
| Cash conversion cycle | -8d | -8d | -6d | -6d | -2d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+24.7%EV / Sales ▲+13.6%EV / EBITDA ▼-6.6%EV / Op. cash flow ▲+3.762Earnings yield ▲+0.006
Profitability
Return on equity ▼-0.604Return on assets ▲+0.014Return on invested capital ▲+0.082Return on capital employed ▲+0.099Operating ROA ▲+0.021Income quality ▼-0.456Tax burden ▲+0.012
Efficiency
Days sales outstanding ▼-0.749Days payables outstanding ▼-1.983Operating cycle ▼-2.253Cash conversion cycle ▼-0.270Capex / Sales ▼-0.001R&D / Sales +0.000
Balance-sheet strength
Current ratio ▼-0.046Net debt / EBITDA ▲+0.323Working capital ▼-3601000000.000Invested capital ▲+750000000.000Intangibles / Total assets ▲+0.034
Change over 5 years
Valuation
Market cap ▲+129.4%EV / Sales ▲+44.2%EV / EBITDA ▼-4.6%EV / Op. cash flow ▲+6.712Earnings yield ▲+0.021
Profitability
Return on equity ▼-1.702Return on assets ▲+0.040Return on invested capital ▲+0.200Return on capital employed ▲+0.238Operating ROA ▲+0.040Income quality ▼-2.153Tax burden ▲+0.190
Efficiency
Days sales outstanding ▼-0.377Days payables outstanding ▲+0.976Operating cycle ▼-4.818Cash conversion cycle ▼-5.794Capex / Sales ▼-0.001R&D / Sales -0.000
Balance-sheet strength
Current ratio ▼-0.100Net debt / EBITDA ▼-0.644Working capital ▼-7572000000.000Invested capital ▼-2601000000.000Intangibles / Total assets ▲+0.005
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-10 | Ro Khanna | Buy | $1,001 - $15,000 | Filing |
| 2026-07-08 | Rick Larsen | Buy | $1,001 - $15,000 | Filing |
| 2026-07-08 | Rick Larsen | Buy | $1,001 - $15,000 | Filing |
| 2026-07-07 | Rick Larsen | Buy | $1,001 - $15,000 | Filing |
| 2025-01-07 | Ritchie Torres | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-07-08 | Rick Larsen | Purchase | $1,001 - $15,000 |
| 2026-06-15 | Jonathan Jackson | Sale | $1,001 - $15,000 |
| 2026-04-08 | Lizzie Fletcher | Sale | $1,001 - $15,000 |
| 2025-12-19 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-12-02 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-12-02 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-12-02 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-10-10 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-10-08 | Jonathan Jackson | Sale | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-23 | Valerie Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-09-10 | Valerie Hoyle | Purchase | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-07-11 | Ritchie Torres | Sale (Full) | $1,001 - $15,000 |
| 2025-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-23 | Jonathan Jackson | Purchase | $1,001 - $15,000 |
| 2025-04-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-24 | Jonathan Jackson | Purchase | $1,001 - $15,000 |
| 2025-03-04 | Jonathan Jackson | Purchase | $1,001 - $15,000 |
| 2025-03-03 | Jonathan Jackson | Purchase | $1,001 - $15,000 |
| 2025-01-24 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2025-01-07 | Ritchie Torres | Purchase | $1,001 - $15,000 |
| 2024-12-18 | Julia Letlow | Purchase | $1,001 - $15,000 |
| 2024-09-12 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-07-01 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-04-04 | Earl Blumenauer | Sale (Partial) | $15,001 - $50,000 |
| 2024-03-20 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-11-16 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-09-08 | Lois Frankel | Sale | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-07-18 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-06-08 | William R. Keating | Purchase | $1,001 - $15,000 |
| 2023-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-05-19 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2023-03-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-23 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-02-14 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-02-10 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2023-01-31 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-11 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-12-06 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-11-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-10-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-10-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-10-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-08-03 | Kathy Manning | Sale (Full) | $1,001 - $15,000 |
| 2022-07-20 | Kathy Manning | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-06-21 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-05-20 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-05-20 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-05-20 | Diana Harshbarger | Purchase | $1,001 - $15,000 |
| 2022-03-14 | Earl Blumenauer | Sale (Full) | $1,001 - $15,000 |
| 2022-03-09 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2022-03-08 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2022-03-02 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2022-02-24 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2022-02-07 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2022-01-21 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-01-20 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2021-10-28 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-09-02 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-03-23 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-11-13 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-04-08 | Lois Frankel | $1,001 - $15,000 | |
| 2019-09-25 | Lois Frankel | Purchase | $1,001 - $15,000 |
| 2019-04-05 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
| 2018-06-14 | Earl Blumenauer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-08-15 BIP Wealth LLC Invests $1.75 Million in McKesson Corporation $MCK BIP Wealth LLC purchased a new stake in McKesson Corporation (NYSE: MCK) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,314 shares of the company''s stock, valued at approximately $1,748,000. A number of other institutional investors have also recently modified their holdings of
- 2026-08-10 Here''s Why McKesson (MCK) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-08-08 McKesson Q1 Earnings Call Highlights McKesson NYSE: MCK reported fiscal first-quarter 2027 results that exceeded its expectations, citing broad-based momentum across its operating businesses and prompting the healthcare services company to raise its full-year adjusted earnings outlook.
- 2026-08-08 McKesson: Solid Q1 Earnings And Management Execution (Rating Upgrade) McKesson delivered strong Q1 results, with EPS up 20% and revenues rising 7.7% while modestly raising FY27 EPS guidance. I see GLP-1-driven momentum decelerating alongside a broader dip in the company''s top-line growth profile. The Wellverse spin-off and prior divestitures are streamlining MCK, potentially justifying a premium multiple versus peers.
- 2026-08-07 McKesson (MCK) is an Incredible Growth Stock: 3 Reasons Why McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
- 2026-08-06 MCK Stock Up as Q1 Earnings Beat on Specialty Growth, Guidance Raised McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.
- 2026-08-06 MCK Q1 Earnings Call Centers on Pharma-Led Guidance Raise McKesson raises fiscal 2027 earnings guidance after pharma profit rises 19%, while specialty demand, oncology growth and disciplined spending shape the call.
- 2026-08-06 Why McKesson (MCK) is a Top Growth Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-08-06 Worried About the Market? These Stocks Have a Track Record of Helping Investors Sleep at Night. These healthcare giants can deliver steady gains.
- 2026-08-06 McKesson Corp (MCK) (Q1 2027) Earnings Call Highlights: Robust Revenue Growth and Raised Guidance Signal Strong Momentum Revenue: $105.4 billion, an increase of 8% year over year.Adjusted Earnings Per Share: $9.93, an increase of 20% year over year.Gross Profit: $3.7 billion, an i